Summit Therapeutics Inc.

SMMT Nasdaq SEC CIK 1599298
Follow Summit Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$208.4M +10.1% vs same quarter last year
EPS, diluted −$0.26 +16.1% vs same quarter last year
Operating cash flow −$159.8M −71.7% vs same quarter last year
Net income by quarter
−$61.2M
−$62.9M
−$565.7M
−$231.8M
−$219.2M
−$189.4M
−$215.7M
−$208.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$1.5B−$1B−$500M$0$500MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25-−$1.1B
FY24$0−$221.3M
FY23$0−$614.9M
FY22$705K−$78.8M
FY21$1.8M−$88.6M
FY20$860K−$52.7M
FY19$57.1M$10.9M
FY18$16.1M−$26.4M
MarginsShare of revenue
  • Operating margin
  • Net margin
−15000%−10000%−5000%0%5000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearOperating marginNet margin
FY25--
FY24--
FY23--
FY22−10225.4%−11174.8%
FY21−4764.3%−4897.8%
FY20−6185.2%−6127.6%
FY199.4%19%
FY18−176.1%−163.6%
Free cash flowOperating cash flow minus capital expenditure
−$400M−$300M−$200M−$100M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$323.6M
FY24−$142.2M
FY23−$76.9M
FY22−$42.2M
FY21−$72.9M
FY20−$48.5M
FY19−$35.3M
FY18−$22.2M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Summit Therapeutics
  • Healthcare median
−15000%−10000%−5000%0%5000%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearSummit TherapeuticsHealthcare median
FY25-−30.6%
FY24-−47%
FY23-−58%
FY22−11174.8%−80.4%
FY21−4897.8%−71.8%
FY20−6127.6%−62.2%
FY1919%−46.2%
FY18−163.6%−49.6%